MicroPort’s Third-Gen Drug Eluting Stent Approved in China

MicroPort Medical, a China medical device maker headquartered in Shanghai’s Zhangjiang Hi-Tech Park, reported that its third-generation drug eluting stent was recently approved for China marketing. According to MicroPort, the advanced design of the Firehawk ® Rapamycin Target Eluting Coronary Stent effectively inhibits restenosis using only one-third the normal amount of rapamycin, improving its safety. The company intends to market the stent internationally and has applied for European approval. More details.... Stock Symbol: (HK: 853) Share this with colleagues: // //